4D Molecular Therapeutics, Inc. $FDMT Holdings Lifted by Armistice Capital LLC

Posted by George Bondi on Jun 18th, 2026

Armistice Capital LLC boosted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 76.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,936,000 shares of the company’s stock after buying an additional 840,000 shares during the period. Armistice Capital LLC’s holdings in 4D Molecular Therapeutics were worth $14,520,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. RA Capital Management L.P. lifted its stake in 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock worth $42,399,000 after acquiring an additional 1,090,000 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in 4D Molecular Therapeutics by 4.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock worth $32,272,000 after acquiring an additional 174,489 shares in the last quarter. State Street Corp lifted its stake in 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after acquiring an additional 1,785,106 shares in the last quarter. Federated Hermes Inc. lifted its stake in 4D Molecular Therapeutics by 33.4% in the 2nd quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company’s stock worth $6,186,000 after acquiring an additional 417,157 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after acquiring an additional 213,264 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

Wall Street Analysts Forecast Growth

FDMT has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Jefferies Financial Group reaffirmed a “buy” rating and set a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Finally, The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.88.

Read Our Latest Research Report on 4D Molecular Therapeutics

4D Molecular Therapeutics Stock Up 8.7%

FDMT opened at $9.42 on Thursday. The firm has a market capitalization of $492.48 million, a P/E ratio of -3.67 and a beta of 2.75. The stock’s 50 day moving average price is $9.44 and its two-hundred day moving average price is $9.14. 4D Molecular Therapeutics, Inc. has a 12-month low of $3.68 and a 12-month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The business had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. As a group, analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

(Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.